Carmen Guaza

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8732201/publications.pdf

Version: 2024-02-01

118 papers	7,393 citations	53794 45 h-index	58581 82 g-index
126 all docs	126 docs citations	126 times ranked	7488 citing authors

#	Article	IF	Citations
1	Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis. Neurotherapeutics, 2021, 18, 920-937.	4.4	18
2	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 685139.	4.8	13
3	Aging and neuroinflammation: Changes in immune cell responses, axon integrity, and motor function in a viral model of progressive multiple sclerosis. Aging Cell, 2021, 20, e13440.	6.7	4
4	2â€arachidonoylglycerol reduces chondroitin sulphate proteoglycan production by astrocytes and enhances oligodendrocyte differentiation under inhibitory conditions. Glia, 2020, 68, 1255-1273.	4.9	13
5	How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process. Gut Microbes, 2020, 12, 1813532.	9.8	24
6	Involvement of Wnt7a in the role of M2c microglia in neural stem cell oligodendrogenesis. Journal of Neuroinflammation, 2020, 17, 88.	7.2	20
7	Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review. Frontiers in Cellular Neuroscience, 2020, 14, 34.	3.7	23
8	Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis. Neurobiology of Disease, 2020, 143, 104994.	4.4	18
9	A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis. Cells, 2020, 9, 906.	4.1	31
10	Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis. Frontiers in Immunology, 2019, 10, 1374.	4.8	35
11	The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia. Brain, Behavior, and Immunity, 2019, 77, 110-126.	4.1	28
12	2â€AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs. Glia, 2018, 66, 1447-1463.	4.9	40
13	Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. Journal of Neuroinflammation, 2018, 15, 64.	7.2	44
14	Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis. PLoS ONE, 2018, 13, e0202590.	2.5	119
15	Gut microbiota, cannabinoid system and neuroimmune interactions: New perspectives in multiple sclerosis. Biochemical Pharmacology, 2018, 157, 51-66.	4.4	31
16	Development of a Fluorescent Bodipy Probe for Visualization of the Serotonin 5-HT_{1A} Receptor in Native Cells of the Immune System. Bioconjugate Chemistry, 2018, 29, 2021-2027.	3.6	21
17	2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination. Journal of Neuroscience, 2017, 37, 8385-8398.	3.6	47
18	Cannabinoid Receptors Modulate Neuronal Morphology and AnkyrinG Density at the Axon Initial Segment. Frontiers in Cellular Neuroscience, 2017, 11, 5.	3.7	23

#	Article	IF	Citations
19	Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55. Journal of Immunology, 2016, 196, 4553-4565.	0.8	21
20	CD200R1 agonist attenuates glial activation, inflammatory reactions, and hypersensitivity immediately after its intrathecal application in a rat neuropathic pain model. Journal of Neuroinflammation, 2016, 13, 43.	7.2	45
21	Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis. Journal of Medicinal Chemistry, 2016, 59, 6753-6771.	6.4	34
22	A <scp>S</scp>ativex^{Â®}â€like combination of phytocannabinoids as a diseaseâ€modifying therapy in a viral model of multiple sclerosis. British Journal of Pharmacology, 2015, 172, 3579-3595.	5.4	58
23	A Basal Tone of 2-Arachidonoylglycerol Contributes to Early Oligodendrocyte Progenitor Proliferation by Activating Phosphatidylinositol 3-Kinase (PI3K)/AKT and the Mammalian Target of Rapamycin (MTOR) Pathways. Journal of NeuroImmune Pharmacology, 2015, 10, 309-317.	4.1	36
24	The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Î”-tetrahydrocannabinol acting through CB1 receptors. Multiple Sclerosis and Related Disorders, 2015, 4, 505-511.	2.0	30
25	Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System. Current Pharmaceutical Design, 2014, 20, 4707-4722.	1.9	69
26	A Cannabigerol Derivative Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis. PLoS ONE, 2014, 9, e94733.	2.5	56
27	A Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis. Angewandte Chemie - International Edition, 2014, 53, 13765-13770.	13.8	91
28	Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus. Progress in Neurobiology, 2013, 101-102, 46-64.	5.7	78
29	The Role of Inflammatory Mediators in Immune-to-Brain Communication during Health and Disease. Mediators of Inflammation, 2013, 2013, 1-3.	3.0	7
30	Understanding Microgliaâ€“Neuron Cross Talk: Relevance of the Microgliaâ€“Neuron Cocultures. Methods in Molecular Biology, 2013, 1041, 215-229.	0.9	14
31	Altered immune function in unaffected first-degree biological relatives of schizophrenia patients. Psychiatry Research, 2012, 200, 1022-1025.	3.3	36
32	A CB1/CB2 receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin. Neuropharmacology, 2012, 63, 385-393.	4.1	37
33	Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases. Neuroscience Letters, 2012, 508, 67-72.	2.1	13
34	A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis. Journal of NeuroImmune Pharmacology, 2012, 7, 1002-1016.	4.1	119
35	Cannabidiolâ€induced apoptosis in murine microglial cells through lipid raft. Glia, 2012, 60, 1182-1190.	4.9	22
36	CD200â€CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia, 2012, 60, 1437-1450.	4.9	113

#	Article	IF	Citations
37	Chemical Probes for the Recognition of Cannabinoid Receptors in Native Systems. Angewandte Chemie - International Edition, 2012, 51, 6896-6899.	13.8	37
38	The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: Evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain, Behavior, and Immunity, 2011, 25, 736-749.	4.1	63
39	Prospects for cannabinoid therapies in basal ganglia disorders. British Journal of Pharmacology, 2011, 163, 1365-1378.	5.4	98
40	Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB1receptors. Journal of Neuroinflammation, 2011, 8, 102.	7.2	51
41	Tissue plasminogen activator prevents white matter damage following stroke. Journal of Experimental Medicine, 2011, 208, 1229-1242.	8.5	72
42	Anandamide enhances ILâ€10 production in activated microglia by targeting CB₂ receptors: Roles of ERK1/2, JNK, and NFâ€ÎºB. Glia, 2010, 58, 135-147.	4.9	149
43	Aggravated experimental autoimmune encephalomyelitis in IL-15 knockout mice. Experimental Neurology, 2010, 222, 235-242.	4.1	33
44	The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiology of Disease, 2009, 33, 57-71.	4.4	107
45	A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochemical Pharmacology, 2009, 77, 86-100.	4.4	85
46	Chapter 9 The Endocannabinoid Anandamide. Vitamins and Hormones, 2009, 81, 207-230.	1.7	19
47	Genderâ€dependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: A possible role for the endocannabinoid system. Developmental Neurobiology, 2008, 68, 1334-1347.	3.0	80
48	Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. European Journal of Neuroscience, 2008, 28, 633-641.	2.6	103
49	Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opinion on Therapeutic Targets, 2008, 12, 185-195.	3.4	37
50	Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E2. Biochemical Journal, 2008, 409, 761-770.	3.7	40
51	Cannabinoid System and Neuroinflammation: Implications for Multiple Sclerosis. NeuroImmunoModulation, 2007, 14, 182-187.	1.8	20
52	Neurobehavioral and Immunological Consequences of Prenatal Immune Activation in Rats. Influence of Antipsychotics. Neuropsychopharmacology, 2007, 32, 1791-1804.	5.4	130
53	Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Molecular and Cellular Neurosciences, 2007, 34, 551-561.	2.2	103
54	Early maternal deprivation and neonatal single administration with a cannabinoid agonist induce long-term sex-dependent psychoimmunoendocrine effects in adolescent rats. Psychoneuroendocrinology, 2007, 32, 636-650.	2.7	79

#	Article	IF	Citations
55	Evidence for Nitric Oxide-Mediated Rapid Locomotor Effects of Corticosterone in a Novel Environment. Annals of the New York Academy of Sciences, 2006, 746, 398-399.	3.8	5
56	The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochemical Pharmacology, 2006, 72, 869-880.	4.4	51
57	Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. Journal of Neurochemistry, 2005, 92, 1327-1339.	3.9	131
58	Differential regulation of typeâ€ƒI and typeâ€ƒII interleukin-1 receptors in focal brain inflammation. European Journal of Neuroscience, 2005, 21, 1205-1214.	2.6	40
59	Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. British Journal of Pharmacology, 2005, 145, 441-448.	5.4	114
60	Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia, 2005, 52, 163-168.	4.9	89
61	The Role of Cannabinoid System on Immune Modulation: Therapeutic Implications on CNS Inflammation. Mini-Reviews in Medicinal Chemistry, 2005, 5, 671-675.	2.4	33
62	Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis. FASEB Journal, 2005, 19, 1338-1340.	0.5	120
63	The Î¹-opioid receptor is involved in the stimulating effect of nicotine on adrenocortical activity but not in nicotine induced anxiety. Behavioural Brain Research, 2005, 163, 212-218.	2.2	27
64	Behavioral, endocrine and immunological characteristics of a murine model of premature aging. Developmental and Comparative Immunology, 2005, 29, 965-976.	2.3	25
65	Nitric oxide released by accessory cells mediates the gastrin-releasing peptide effect on murine lymphocyte chemotaxis. Regulatory Peptides, 2005, 131, 46-53.	1.9	4
66	Functional responses to the cannabinoid agonist WIN 55,212-2 in neonatal rats of both genders: influence of weaning. Pharmacology Biochemistry and Behavior, 2004, 78, 593-602.	2.9	16
67	Chronic treatment with CP 55,940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood. Psychopharmacology, 2003, 170, 301-308.	3.1	128
68	Endogenous Interleukin-1 Receptor Antagonist Mediates Anti-Inflammatory and Neuroprotective Actions of Cannabinoids in Neurons and Glia. Journal of Neuroscience, 2003, 23, 6470-6474.	3.6	185
69	Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis. Journal of Neuroscience, 2003, 23, 2511-2516.	3.6	294
70	Interleukin-1 Regulates Proliferation and Differentiation of Oligodendrocyte Progenitor Cells. Molecular and Cellular Neurosciences, 2002, 20, 489-502.	2.2	189
71	Effects of 14-methoxymetopon, a potent opioid agonist, on the responses to the tail electric stimulation test and plus-maze activity in male rats: neuroendocrine correlates. Brain Research Bulletin, 2002, 57, 661-666.	3.0	23
72	Theiler's virus infection induces the expression of cyclooxygenase-2 in murine astrocytes: inhibition by the anti-inflammatory cytokines interleukin-4 and interleukin-10. Neuroscience Letters, 2002, 324, 237-241.	2.1	34

#	Article	IF	Citations
73	Cannabinoids Promote Oligodendrocyte Progenitor Survival: Involvement of Cannabinoid Receptors and Phosphatidylinositol-3 Kinase/Akt Signaling. Journal of Neuroscience, 2002, 22, 9742-9753.	3.6	390
74	Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. Developmental Brain Research, 2002, 136, 85-92.	1.7	74
75	Prenatal Immune Challenge Disrupts Sensorimotor Gating in Adult Rats Implications for the Etiopathogenesis of Schizophrenia. Neuropsychopharmacology, 2002, 26, 204-215.	5.4	279
76	Role of CB₁ and CB₂ receptors in the inhibitory effects of cannabinoids on lipopolysaccharideâ€induced nitric oxide release in astrocyte cultures. Journal of Neuroscience Research, 2002, 67, 829-836.	2.9	133
77	Interleukin-4 and interleukin-10 modulate nuclear factor ÎºB activity and nitric oxide synthase-2 expression in Theiler's virus-infected brain astrocytes. Journal of Neurochemistry, 2002, 81, 1242-1252.	3.9	33
78	Spatial learning deficit in transgenic mice that conditionally over-express GSK-3Î² in the brain but do not form tau filaments. Journal of Neurochemistry, 2002, 83, 1529-1533.	3.9	323
79	LPS/IFNâ€Îł cytotoxicity in oligodendroglial cells: role of nitric oxide and protection by the antiâ€inflammatory cytokine ILâ€10. European Journal of Neuroscience, 2001, 13, 493-502.	2.6	150
80	Re-evaluation of nestin as a marker of oligodendrocyte lineage cells. Microscopy Research and Technique, 2001, 52, 753-765.	2.2	51
81	Induction of COX-2 and PGE2 biosynthesis by IL-1Î² is mediated by PKC and mitogen-activated protein kinases in murine astrocytes. British Journal of Pharmacology, 2000, 131, 152-159.	5.4	180
82	Naltrindole administration during the preweanling period and manipulation affect adrenocortical reactivity in young rats. Developmental Brain Research, 1999, 112, 135-137.	1.7	11
83	Increased cerebrospinal fluid cAMP levels in Alzheimer's disease. Brain Research, 1999, 846, 265-267.	2.2	66
84	Dexamethasone regulation of interleukin-1-receptors in the hippocampus of Theiler's virus-infected mice: effects on virus-mediated demyelination. European Journal of Pharmacology, 1999, 372, 75-83.	3.5	23
85	The endogenous cannabinoid anandamide potentiates interleukinâ€6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptorâ€mediated pathway. FEBS Letters, 1998, 433, 139-142.	2.8	100
86	Anandamide suppresses nitric oxide and TNF-Î± responses to TheilerÊ¼s virus or endotoxin in astrocytes. NeuroReport, 1997, 8, 1929-1933.	1.2	105
87	Experienceâ€dependent Facilitating Effect of Corticosterone on Spatial Memory Formation in the Water Maze. European Journal of Neuroscience, 1997, 9, 637-642.	2.6	377
88	Endotoxin administration induced differential neurochemical activation of the rat brain stem nuclei. Brain Research Bulletin, 1996, 40, 151-156.	3.0	40
89	Regional and temporal modulation of brain glycoprotein synthesis by corticosterone. NeuroReport, 1996, 7, 2819-2822.	1.2	12
90	Nitric Oxide Synthesis Inhibitors Prevent Rapid Behavioral Effects of Corticosterone in Rats. Neuroendocrinology, 1996, 63, 446-453.	2.5	52

#	Article	IF	Citations
91	Novelty-related Rapid Locomotor Effects of Corticosterone in Rats. European Journal of Neuroscience, 1996, 8, 794-800.	2.6	183
92	Evidence for cyclooxygenase activation by nitric oxide in astrocytes. Glia, 1995, 15, 167-172.	4.9	56
93	Cytokine Regulation of Corticosteroid Receptors in the Rat Hippocampus: Effects of Interleukin-1, Interleukin-6, Tumor Necrosis Factor and Lipopolysaccharide. Neuroendocrinology, 1995, 62, 47-54.	2.5	24
94	Modulation of IL-1 receptor in mice hippocampus during Theiler's virus encephalomyelitis, an experimental model for multiple sclerosis (MS). Journal of Neuroimmunology, 1994, 54, 177.	2.3	0
95	Corticosteroid Regulation of IL-1 Receptors in the Mouse Hippocampus: Effects of Glucocorticoid Treatment, Stress, and Adrenalectomy. Neuroendocrinology, 1994, 59, 120-128.	2.5	30
96	Interleukin-1-Beta Induces Pituitary Adrenocorticotropin Secretion: Evidence for Glucocorticoid Modulation. Neuroendocrinology, 1992, 55, 648-654.	2.5	44
97	Is the Adrenal Cortex a Putative Site for the Action of Interleukin-1?. Hormone and Metabolic Research, 1992, 24, 48-49.	1.5	13
98	Adrenalectomy does not change CRF secretion induced by interleukin-1 from rat perifused hypothalami. Regulatory Peptides, 1992, 41, 237-247.	1.9	6
99	Role of arachidonic acid metabolism on corticotropin-releasing factor (CRF)-release induced by interleukin-1 from superfused rat hypothalami. Journal of Neuroimmunology, 1992, 39, 57-66.	2.3	29
100	Effects of HPA hormones on adapted lymphocyte responsiveness to repeated stress. Brain Research Bulletin, 1992, 28, 581-585.	3.0	18
101	Behavioral, neuroendocrine, and immunological outcomes of escapable or inescapable shocks. Physiology and Behavior, 1992, 51, 651-656.	2.1	21
102	Activity of the hypothalamic-pituitary-adrenal axis in mice selected for left- or right-handedness. Brain Research, 1992, 589, 302-306.	2.2	10
103	Mutually Antagonistic Effects of Corticosterone and Prolactin on Rat Lymphocyte Proliferation. Neuroendocrinology, 1992, 56, 574-581.	2.5	26
104	Administration of leu-enkephalin impairs the acquisition of preference for ethanol. Psychopharmacology, 1990, 100, 350-354.	3.1	7
105	Enkephalins interfere with early phases of voluntary ethanol drinking. Peptides, 1990, 11, 697-702.	2.4	10
106	Effects of the kappa opioid receptor antagonist MR-2266-BS on the acquisition of ethanol preference. Life Sciences, 1990, 46, 1119-1129.	4.3	7
107	D-Ala2-Met5-enkephalinamide impairs the acquisition of ethanol preference without influencing sucrose preference. Physiology and Behavior, 1990, 48, 435-439.	2.1	12
108	Î²-Endorphin administration interferes with the acquisition and initial maintenance of ethanol preference in the rat. Physiology and Behavior, 1989, 45, 87-92.	2.1	10

#	Article	IF	Citations
109	Naloxone decreases ethanol consumption within a free choice paradigm in rats. Pharmacology Biochemistry and Behavior, 1988, 29, 39-43.	2.9	39
110	Involvement of kappa type opioids on ethanol drinking. Life Sciences, 1988, 42, 1067-1075.	4.3	34
111	Effects of adrenaline on the acquisition and maintenance of ethanol preference in a taste conditioning paradigm. Psychopharmacology, 1986, 90, 336-40.	3.1	10
112	Modifications in adrenal hormones response to ethanol by prior ethanol dependence. Pharmacology Biochemistry and Behavior, 1985, 22, 357-360.	2.9	8
113	Prolonged ethanol consumption influences shuttle box and passive avoidance performance in rats. Physiology and Behavior, 1985, 34, 163-165.	2.1	10
114	Effect of naloxone administration upon responses of adrenal hormones to withdrawal from ethanol. Psychopharmacology, 1984, 82, 181-184.	3.1	11
115	Adrenocortical response to acute and chronic ethanol administration in rats. Psychopharmacology, 1983, 79, 173-176.	3.1	61
116	Adrenomedullary responses to acute and chronic ethanol administration to rats. Biochemical Pharmacology, 1983, 32, 3091-3095.	4.4	9
117	The effects of acute and chronic administration of morphine on the turnover of brain and adrenal catecholamines in rats. Psychopharmacology, 1980, 68, 43-49.	3.1	19
118	Effects of acute and prolonged administration of chlordiazepoxide upon the pituitary-adrenal activity and brain catecholamines in sound stressed and unstressed rats. Neuroscience, 1980, 5, 2289-2295.	2.3	33